Mettler-Toledo International Inc. (0K10.L)
USD 1248.03
(-0.62%)
USD 1248.03
(-0.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 788.77 Million USD | -9.6% |
| 2022 | 872.5 Million USD | 13.46% |
| 2021 | 768.98 Million USD | 27.58% |
| 2020 | 602.73 Million USD | 7.42% |
| 2019 | 561.1 Million USD | 9.46% |
| 2018 | 512.61 Million USD | 36.34% |
| 2017 | 375.97 Million USD | -2.18% |
| 2016 | 384.37 Million USD | 8.94% |
| 2015 | 352.82 Million USD | 4.31% |
| 2014 | 338.24 Million USD | 10.5% |
| 2013 | 306.09 Million USD | 5.24% |
| 2012 | 290.84 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 221.81 Million USD | 24.96% |
| 2024 Q1 | 177.5 Million USD | -3.94% |
| 2023 Q3 | 201.63 Million USD | -5.75% |
| 2023 Q1 | 188.42 Million USD | -29.12% |
| 2023 Q4 | 184.79 Million USD | -8.35% |
| 2023 Q2 | 213.92 Million USD | 13.53% |
| 2023 FY | 788.77 Million USD | -9.6% |
| 2022 FY | 872.5 Million USD | 13.46% |
| 2022 Q3 | 220.59 Million USD | 4.02% |
| 2022 Q2 | 212.07 Million USD | 21.88% |
| 2022 Q1 | 174 Million USD | -24.63% |
| 2022 Q4 | 265.83 Million USD | 20.51% |
| 2021 Q3 | 203.68 Million USD | 10.24% |
| 2021 Q4 | 230.87 Million USD | 13.35% |
| 2021 Q1 | 149.66 Million USD | -30.81% |
| 2021 Q2 | 184.76 Million USD | 23.45% |
| 2021 FY | 768.98 Million USD | 27.58% |
| 2020 Q2 | 126.56 Million USD | 28.99% |
| 2020 Q4 | 216.29 Million USD | 33.71% |
| 2020 FY | 602.73 Million USD | 7.42% |
| 2020 Q1 | 98.11 Million USD | -49.1% |
| 2020 Q3 | 161.76 Million USD | 27.82% |
| 2019 FY | 561.1 Million USD | 9.46% |
| 2019 Q4 | 192.74 Million USD | 48.96% |
| 2019 Q3 | 129.39 Million USD | 1.76% |
| 2019 Q2 | 127.16 Million USD | 13.73% |
| 2019 Q1 | 111.8 Million USD | -38.29% |
| 2018 Q1 | 93.3 Million USD | 21.21% |
| 2018 Q3 | 126.65 Million USD | 13.62% |
| 2018 FY | 512.61 Million USD | 36.34% |
| 2018 Q2 | 111.46 Million USD | 19.47% |
| 2018 Q4 | 181.18 Million USD | 43.06% |
| 2017 FY | 375.97 Million USD | -2.18% |
| 2017 Q2 | 101.58 Million USD | 9.86% |
| 2017 Q4 | 76.97 Million USD | -26.65% |
| 2017 Q3 | 104.95 Million USD | 3.32% |
| 2017 Q1 | 92.46 Million USD | -32.89% |
| 2016 Q4 | 137.77 Million USD | 35.96% |
| 2016 FY | 384.37 Million USD | 8.94% |
| 2016 Q3 | 101.33 Million USD | 27.32% |
| 2016 Q2 | 79.58 Million USD | 21.19% |
| 2016 Q1 | 65.67 Million USD | -46.76% |
| 2015 Q2 | 77.55 Million USD | 23.01% |
| 2015 Q3 | 88.86 Million USD | 14.58% |
| 2015 FY | 352.82 Million USD | 4.31% |
| 2015 Q1 | 63.05 Million USD | -47.97% |
| 2015 Q4 | 123.35 Million USD | 38.81% |
| 2014 Q4 | 121.17 Million USD | 42.56% |
| 2014 FY | 338.24 Million USD | 10.5% |
| 2014 Q1 | 58.05 Million USD | -47.3% |
| 2014 Q2 | 74.02 Million USD | 27.51% |
| 2014 Q3 | 84.99 Million USD | 14.83% |
| 2013 Q2 | 69.06 Million USD | 31.44% |
| 2013 Q3 | 74.32 Million USD | 7.62% |
| 2013 Q4 | 110.16 Million USD | 48.21% |
| 2013 FY | 306.09 Million USD | 5.24% |
| 2013 Q1 | 52.54 Million USD | -49.78% |
| 2012 FY | 290.84 Million USD | 0.0% |
| 2012 Q4 | 104.63 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 614.804% |
| Dynavax Technologies Corporation | -6.38 Million USD | 12445.876% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -59837.538% |
| Perrigo Company plc | -12.7 Million USD | 6310.85% |
| Illumina, Inc. | -1.16 Billion USD | 167.94% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 86.843% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 277.638% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 109.134% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 41.916% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 813.445% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 80.049% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 2078.871% |
| Waters Corporation | 642.23 Million USD | -22.818% |
| Biogen Inc. | 1.16 Billion USD | 32.066% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 405.928% |
| Evolus, Inc. | -61.68 Million USD | 1378.719% |
| Adicet Bio, Inc. | -142.65 Million USD | 652.915% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 765.562% |
| bluebird bio, Inc. | -211.91 Million USD | 472.218% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 476.958% |
| FibroGen, Inc. | -284.23 Million USD | 377.512% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 36.389% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 1868.429% |
| Homology Medicines, Inc. | -53.74 Million USD | 1567.685% |
| Geron Corporation | -184.12 Million USD | 528.388% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 279.169% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 620.357% |
| Myriad Genetics, Inc. | -112 Million USD | 804.266% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 1018.305% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 263.922% |
| Zoetis Inc. | 2.34 Billion USD | 66.349% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 1555.632% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -370.505% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 78.208% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 1969.186% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 315.345% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 385.659% |
| Verastem, Inc. | -87.36 Million USD | 1002.833% |
| Nektar Therapeutics | -276.05 Million USD | 385.731% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 429.704% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 991.466% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 247.166% |
| OPKO Health, Inc. | -188.86 Million USD | 517.646% |
| Exelixis, Inc. | 207.76 Million USD | -279.649% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -215.89% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -643.149% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 1760.41% |
| uniQure N.V. | -308.47 Million USD | 355.7% |
| Imunon, Inc. | -19.51 Million USD | 4141.911% |
| Blueprint Medicines Corporation | -506.98 Million USD | 255.582% |
| Insmed Incorporated | -749.56 Million USD | 205.231% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -180.112% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 324.029% |
| TG Therapeutics, Inc. | 12.67 Million USD | -6124.574% |
| Incyte Corporation | 597.59 Million USD | -31.991% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 203.718% |